Prostate cancer · 8 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Abiraterone and Niraparib Variant #01 | BRCA | R 78 419 | 28d | — | — | ~2 | ~R 156 837 indirect | — |
Olaparib monotherapy Variant #01 | BRCA | R 19 741 | 28d | — | 19.1 mo | 2 | R 39 483 PFS proxy | 1 |
Enzalutamide monotherapy Variant #01 | BRCA | R 14 528 | 28d | 4.2 mo | 17.5 mo | 2 | R 29 057 PFS proxy | 13 |
Abiraterone monotherapy Variant #01 | BRCA | R 10 320 | 28d | 4.9 mo | 15.4 mo | 2 | R 20 639 PFS proxy | 9 |
Docetaxel and Prednisone Variant #01 | BRCA | R 4 886 | 42d | — | 21.2 mo | 5 | R 24 429 PFS proxy | 13 |
Docetaxel and Prednisolone Variant #01 | BRCA | R 1 630 | 14d | 8.3 mo | 19.1 mo | 2 | R 3 261 PFS proxy | 3 |
Abiraterone and Niraparib (combined pill) Variant #01 Partial | BRCA | — | 28d | — | — | ~2 | — | — |
Rucaparib monotherapy Variant #01 Partial | BRCA | — | 28d | ~20.2 mo | ~27.7 mo | ~2 | — | 7 |
8 of 8 regimens shown